Across TCGA pan-cancer cohorts, CXCL17 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CXCL17 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CXCL17 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CXCL17 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where CXCL17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.937	0.742	.003	16	view →
HNSC	OS	Tertile	All	0.812	0.599	.010	14	view →
PDAC	DFS	Quartile	All	0.733	0.267	.002	8	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CXCL17 tumor-vs-normal RNA expression · all CXCL17 data types